Matching plasma and tissue miRNA expression analysis to detect viable ovarian germ cell tumors
PLOS One · 2025
DOI: 10.1371/journal.pone.0322477 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Arkhjamil Angeles und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Medical Oncology Division, BC Cancer, Vancouver Centre, University of British Columbia, BC, Canada. Hauptthemen laut MEDLINE: MicroRNAs, Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research.
Abstract (Originalsprache)
Purpose
MicroRNAs (miRNAs) are emerging as circulating biomarkers in germ cell tumors (GCT) with potential to guide management. Their role and expression patterns are more established in testicular GCTs, while lesser data exist in ovarian GCTs (OGCT).
Methods
Patients diagnosed with OGCT with plasma and tumor tissue available in our provincial biobank were included. Total RNA was extracted, and RT-qPCR was performed to measure miR-371–3 and miR-302/367 levels. Healthy plasma and ovarian tissue served as controls. Statistical analyses were performed using ANOVA and the Mann-Whitney U test. Clinicopathologic data was collected by chart review.
Results
From 2007 to 2022, 23 patients with OGCT were identified: 13 with viable non-teratoma germ cell (VNTGC) and 10 with immature teratoma germ cell (ITGC) tumors. Compared to healthy controls, all patients with VNTGC but not ITGC tumors had significantly higher miRNA levels in preoperative plasma and tumor tissue. Plasma miRNA kinetics correlated with disease burden, decreasing to undetectable levels following treatment, and increasing significantly upon relapse.
Conclusion
MiR-371–3 and miR-302/367 are highly expressed in ovarian VNTGC but not ITGC tumors, and their plasma levels correlate with disease burden. Future studies validating these findings in a larger cohort are needed to develop miRNAs as circulating biomarkers for clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Medical Oncology Division, BC Cancer, Vancouver Centre, University of British Columbia, BC, Canada.
- Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
- Departments of Obstetrics and Gynecology and Clinical Research, University of British Columbia and BC Cancer, Vancouver, BC, Canada.
- Testicular Cancer Commons, Beaverton, Oregon, United States of America.
ORCID-Profile: Lucia Nappi
Förderung
- Health Research
Zitieren
APA
Angeles, A., Khazamipour, N., Dhillon, G., Janfaza, S., Oo, H. Z., Ozgun, G., Moeen, A., Nichols, C., Kollmannsberger, C., Carey, M. S., & Nappi, L. (2025). Matching plasma and tissue miRNA expression analysis to detect viable ovarian germ cell tumors. PLOS One. https://doi.org/10.1371/journal.pone.0322477
Vancouver
Angeles A, Khazamipour N, Dhillon G, Janfaza S, Oo HZ, Ozgun G, et al. Matching plasma and tissue miRNA expression analysis to detect viable ovarian germ cell tumors. PLOS One. 2025. doi:10.1371/journal.pone.0322477
BibTeX
@article{Angeles2025,
author = {Angeles, Arkhjamil and Khazamipour, Nastaran and Dhillon, Gurdial and Janfaza, Sajjad and Oo, Htoo Zarni and Ozgun, Guliz and Moeen, Alireza and Nichols, Craig and Kollmannsberger, Christian and Carey, Mark S and Nappi, Lucia},
title = {Matching plasma and tissue miRNA expression analysis to detect viable ovarian germ cell tumors},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0322477}
}
EUVIMED